scholarly article | Q13442814 |
P50 | author | Mark W. Ball | Q41496168 |
Ashley E. Ross | Q57023811 | ||
Edward M Schaeffer | Q62069731 | ||
Alan W Partin | Q62089936 | ||
Misop Han | Q63022456 | ||
Debasish Sundi | Q63253312 | ||
Jonathan I. Epstein | Q88404078 | ||
H Ballentine Carter | Q114718059 | ||
P2093 | author name string | Trinity J Bivalacqua | |
Phillip M Pierorazio | |||
Farzana A Faisal | |||
Elizabeth B Humphreys | |||
P2860 | cites work | Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men | Q33702311 |
Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer | Q35605945 | ||
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging | Q37611898 | ||
Active surveillance for clinically localized prostate cancer--a systematic review | Q38194533 | ||
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy | Q39797017 | ||
High diagnostic ability of multiparametric magnetic resonance imaging to detect anterior prostate cancer missed by transrectal 12-core biopsy | Q40101873 | ||
Predictors of Gleason score upgrading in a large African-American population | Q40125227 | ||
Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens | Q41727000 | ||
Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6. | Q41863428 | ||
The clinical features of anterior prostate cancers | Q43034645 | ||
Expanded criteria to identify men eligible for active surveillance of low risk prostate cancer at Johns Hopkins: a preliminary analysis | Q43766423 | ||
Value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours | Q44623612 | ||
Pretreatment predictors of time to cancer specific death after prostate specific antigen failure | Q44952969 | ||
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience | Q45133435 | ||
Biological determinants of cancer progression in men with prostate cancer. | Q51090543 | ||
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 | ||
Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy | Q59649550 | ||
Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer | Q71606146 | ||
Correlation of pathologic findings with progression after radical retropubic prostatectomy | Q72079964 | ||
Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy | Q73203851 | ||
Calculated volume of prostate cancer identifies patients with clinical stage T1C disease at high risk of biochemical recurrence after radical prostatectomy: a preliminary study | Q74107626 | ||
Contemporary evaluation of the D'amico risk classification of prostate cancer | Q80168461 | ||
Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors | Q80388277 | ||
P433 | issue | 6b | |
P304 | page(s) | E120-E129 | |
P577 | publication date | 2014-08-13 | |
P1433 | published in | BJU International | Q4835773 |
P1476 | title | Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature | |
P478 | volume | 114 |